Defining and measuring tolerability in pediatric, adolescent, and young adult oncology: The essential voices
Cancer · 2025
DOI: 10.1002/cncr.35947 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, 2025. Verfasst von Susan K Parsons und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Neoplasms, Medical Oncology, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
In this review on the status of tolerability in pediatric oncology, the authors address the relevance and meaning of this important concept and offer a definition to represent treatment tolerability experiences of pediatric, adolescent, and young adult oncology patients. The authors acknowledge the incomplete progress of tolerability research in pediatric oncology clinical trials while describing the recent advances in validating relevant measures and embedding these in pediatric oncology clinical trials to document the symptom burden of specific cancer treatments. They advocate for the consistent use of three voices—patient, caregiver, and clinician—in pediatric oncology to achieve accurate and comprehensive estimates of treatment tolerability while recognizing that a primary voice may be necessary to match the main aim or goal of the proposed research. Future steps include establishing the validity of tolerability measures and methods in patients younger than 7 years and a careful examination of tolerability issues into survivorship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
- Department of Pediatrics, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
- Department of Medicine, Division of Hematology/Oncology, Institute for Clinical Research and Health Policy Studies, Boston, Massachusetts, USA.
- University of Wisconsin-Madison School of Nursing, Madison, Wisconsin, USA.
- Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
- Department of Pediatrics, Rutgers Cancer Institute, New Brunswick, New Jersey, USA.
ORCID-Profile: Katie A Greenzang, Philip J Lupo, Abby R Rosenberg, Pamela S Hinds
Förderung
- NCI NIH HHS
Zitieren
APA
Parsons, S. K., Montgomery, K. E., Brackett, J., Devine, K. A., Embry, L. M., Greenzang, K. A., Lupo, P. J., Nuño, M. M., Rosenberg, A. R., Roth, M. E., Zupanec, S. M., & Hinds, P. S. (2025). Defining and measuring tolerability in pediatric, adolescent, and young adult oncology: The essential voices. Cancer. https://doi.org/10.1002/cncr.35947
Vancouver
Parsons SK, Montgomery KE, Brackett J, Devine KA, Embry LM, Greenzang KA, et al. Defining and measuring tolerability in pediatric, adolescent, and young adult oncology: The essential voices. Cancer. 2025. doi:10.1002/cncr.35947
BibTeX
@article{Parsons2025,
author = {Parsons, Susan K and Montgomery, Kathleen E and Brackett, Julienne and Devine, Katie A and Embry, Leanne M and Greenzang, Katie A and Lupo, Philip J and Nuño, Michelle M and Rosenberg, Abby R and Roth, Michael E and Zupanec, Sue M and Hinds, Pamela S},
title = {Defining and measuring tolerability in pediatric, adolescent, and young adult oncology: The essential voices},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35947}
}
EUVIMED